Search results for "Second Primary"

showing 10 items of 61 documents

Spontaneous and Radiation-Induced Chromosome Aberrations in Primary Fibroblasts of Patients With Pediatric First and Second Neoplasms

2020

Frontiers in oncology 10, 1338 (2020). doi:10.3389/fonc.2020.01338

0301 basic medicineCancer ResearchDNA repairSomatic cell610Chromosomal translocationlcsh:RC254-28203 medical and health sciences0302 clinical medicineRadiation sensitivityChromosome instabilitymedicinechildhood cancerddc:610spontaneous chromosomal instabilityOriginal Researchmedicine.diagnostic_testbusiness.industryChromosomeradiation sensitivitysecond primary malignancieslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrimary Neoplasm030104 developmental biologychromosome aberrationsOncology030220 oncology & carcinogenesisCancer researchbusinessionizing radiationSecond primary malignancies ; Radiation sensitivity ; Chromosome aberrations ; Childhood cancer ; Spontaneous chromosomal instability ; Ionizing radiationFluorescence in situ hybridization
researchProduct

Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies

2021

Simple Summary Childhood cancers are mostly of unknown etiology and represent devastating diagnoses. The clinical benefits of steadily increasing tumor control and survival rates are countered by severe and fatal health consequences from genotoxic therapies in long-term survivors of pediatric cancers. Among them, iatrogenic second primary malignancies represent the heaviest burden for the patient. Therefore, particularly in pediatric tumor patients, the reduction of genotoxic treatments and the use of targeted or immune-based oncologic strategies are of high clinical interest. The knowledge of therapy-associated as well as intrinsic risk factors for late sequelae of antineoplastic treatment…

0301 basic medicineCancer Researchmedicine.medical_specialtyetiologymedicine.medical_treatmentPopulationReviewchemotherapyTargeted therapy03 medical and health sciences0302 clinical medicineEpidemiologymedicinechildhood cancerlate-effectseducationIntensive care medicineradiotherapyRC254-282education.field_of_studyChemotherapybusiness.industryCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasetargeted therapyPediatric cancerRadiation therapy030104 developmental biologyOncology030220 oncology & carcinogenesisEtiologyepidemiologyimmunotherapybusinesssecond primary malignancyCancers
researchProduct

Comparison of time and dose dependent gene expression and affected pathways in primary human fibroblasts after exposure to ionizing radiation

2020

Abstract Background Exposure to ionizing radiation induces complex stress responses in cells, which can lead to adverse health effects such as cancer. Although a variety of studies investigated gene expression and affected pathways in human fibroblasts after exposure to ionizing radiation, the understanding of underlying mechanisms and biological effects is still incomplete due to different experimental settings and small sample sizes. Therefore, this study aims to identify the time point with the highest number of differentially expressed genes and corresponding pathways in primary human fibroblasts after irradiation at two preselected time points. Methods Fibroblasts from skin biopsies of…

0301 basic medicineIonizing radiationTime FactorsDNA damageCellHigh doseIonizing radiationlcsh:BiochemistryGene-radiation interaction03 medical and health sciences0302 clinical medicineRadiation IonizingGene expressionGeneticsmedicineHumanslcsh:QD415-436IrradiationMolecular BiologyGeneGenetics (clinical)Gene-radiation interaction ; RNA sequencing ; Childhood cancer ; High dose ; Fibroblasts ; Low dose ; Second primary neoplasm ; IPA ; Ionizing radiationCells CulturedChemistryGene Expression Profilinglcsh:RM1-950Second primary neoplasmCancerComputational BiologyRNA sequencingDose-Response Relationship RadiationFibroblastsmedicine.diseaseCell biology030104 developmental biologymedicine.anatomical_structurelcsh:Therapeutics. PharmacologyLow doseGene Expression Regulation030220 oncology & carcinogenesisIPACase-Control StudiesMolecular MedicineSignal transductionChildhood cancerResearch ArticleSignal TransductionMolecular Medicine
researchProduct

mRCC Outcome in the Treatment of Metastatic Renal Cell Carcinoma - A German Single-center Real-world Experience.

2018

Background/Aim: Since the advent of targeted therapeutics, paradigms in metastatic renal cell carcinoma (mRCC) treatment have changed. We investigated if efficacy and safety data from randomized controlled trials can be transferred into real-world settings. Patients and Methods: All patients with mRCC treated from 2006-2015 at the Department of Urology (Marburg-Germany) were retrospectively analyzed. Collected data include: Patient demographics, tumor characteristics, efficacy, safety, and used therapy sequences. Results: In total, 197 patients with mRCC were identified. About one third of patients reached third-line therapy. Median overall survival in real-world amounted to 25.8 months wit…

0301 basic medicineOncologyAdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentSingle CenterGeneral Biochemistry Genetics and Molecular BiologyTyrosine-kinase inhibitorTargeted therapylaw.invention03 medical and health sciences0302 clinical medicineRisk groupsRandomized controlled trialRenal cell carcinomalawRisk FactorsInternal medicineGermanymedicineOverall survivalHumansMolecular Targeted TherapyNeoplasm MetastasisSurvival rateCarcinoma Renal CellProtein Kinase InhibitorsAgedRandomized Controlled Trials as TopicRetrospective StudiesPharmacologybusiness.industryNeoplasms Second PrimaryMiddle Agedmedicine.diseaseProgression-Free Survival030104 developmental biologyTreatment Outcome030220 oncology & carcinogenesisFemalebusinessResearch ArticleIn vivo (Athens, Greece)
researchProduct

Prognostic Factors of Survival among Women with Metastatic Breast Cancer and Impact of Primary or Secondary Nature of Disease on Survival: A French P…

2016

We aim to determine whether differences in survival exist between two populations of women with metastatic breast cancer (MBC) and to identify prognostic factors of survival after metastasis diagnosis. Data on women with MBC diagnosed between 2000 and 2011 were provided by the Cote d'Or Breast cancer registry. Survival rates and median overall survival (OS) after metastasis diagnosis were determined using the Kaplan–Meier method and prognostic factors were determined in a Cox proportional hazard model. Overall, 282 women with primary MBC and 340 with secondary MBC were included. A 2-year survival rate was significantly better in women with primary MBC (50.8% [95% CI: 47.8–53.8%] versus 44.5…

0301 basic medicineOncologyAdultmedicine.medical_specialtyPopulationBreast NeoplasmsDiseaseKaplan-Meier EstimateMetastasis03 medical and health sciences0302 clinical medicineBreast cancerInternal medicineEpidemiologyInternal MedicinemedicineHumansRegistriesskin and connective tissue diseaseseducationSurvival rateAgedProportional Hazards ModelsAged 80 and overeducation.field_of_studyProportional hazards modelbusiness.industryNeoplasms Second PrimaryMiddle Agedmedicine.diseasePrognosisMetastatic breast cancerSurvival Rate030104 developmental biologyOncology030220 oncology & carcinogenesisSurgeryFemaleFrancebusinessThe breast journal
researchProduct

Response: Methods for second primary cancers evaluation have to be standardized

2017

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industryIncidence (epidemiology)Endometrial cancerCancerSecond primary cancermedicine.diseaseSecond Primary CancersCancer registry03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineEpidemiology of cancermedicineEtiologybusinessInternational Journal of Cancer
researchProduct

Epidemiology and biological characteristics of male breast cancer in Italy.

2020

Aim: To evaluate the epidemiology of male breast cancer (MBC) in Italy and to describe incidence and survival data in relation to age, morphology, year of incidence, geographic area, and possible association with other cancers compared with female BC. Methods: Cases were extracted from 40 Italian Cancer Registries. Standardized incidence rates (SIR), age-specific rates, and 5-year survival were calculated. The association with second tumors was also evaluated. All data were compared with data from female BCs. Results: In the 2000–2014 period, 2175 new cases of MBC were registered, with an SIR of 1.7 × 100,000. The incidence showed a slight upward trend and increased with increasing age. The…

0301 basic medicineOncologyMaleReceptor ErbB-2Sex Factormale breast cancerKaplan-Meier Estimate0302 clinical medicineclinical and biological characteristics; male breast cancer; second cancers; stage; survivalMedicinePharmacology (medical)Age FactorBreastRegistriesAged 80 and overclinical and biological characteristicsGeographyIncidence (epidemiology)IncidenceCarcinoma Ductal BreastAge FactorsNeoplasms Second PrimaryGeneral MedicineMiddle Agedsecond cancersSurvival RateOncologyItalyReceptors Estrogen030220 oncology & carcinogenesisMale breast cancerFemaleReceptors ProgesteroneBreast NeoplasmYoung Adult.Adultmedicine.medical_specialtyBreast NeoplasmssurvivalBreast Neoplasms Male03 medical and health sciencesYoung AdultBreast cancerSex FactorsInternal medicineHumansRadiology Nuclear Medicine and imagingRisk factorSurvival rateCancer stagingAgedbusiness.industryCancermedicine.diseasestageCancer registry030104 developmental biologyKi-67 AntigenClinical and biological characteristicbusinessBreast cancer (Tokyo, Japan)
researchProduct

Biology and management of therapy-related acute promyelocytic leukemia.

2013

Therapy-related acute promyelocytic leukemia (t-APL) has been increasingly reported after exposure to cytotoxic and/or immunosuppressive agents given for prior malignancies or autoimmune diseases. t-APL represents both a model for better understanding human leukemogenesis and an interesting therapeutic subset which requires specific adaptations for optimal management.We discuss here potential risk factors for t-APL development and the main biologic and clinical characteristics of t-APL as compared to de-novo APL.In addition, we review therapeutic results obtained in patients with t-APL receiving conventional retinoic acid and chemotherapy and discuss new treatment opportunities with minimal…

Acute promyelocytic leukemiaAdultMaleCancer ResearchRetinoic acidAntineoplastic AgentsTretinoinAcuteArsenicalschemistry.chemical_compoundArsenic TrioxideLeukemia Promyelocytic Acuteimmune system diseasesRisk FactorsNeoplasmsCytotoxic T cellMedicineHumansArsenic trioxideneoplasmsAdult; Antineoplastic Agents; Arsenicals; Early Diagnosis; Female; Humans; Leukemia Promyelocytic Acute; Male; Middle Aged; Neoplasms Second Primary; Oxides; Retrospective Studies; Risk Factors; TretinoinRetrospective StudiesPromyelocyticTherapy relatedLeukemiabusiness.industryNeoplasms Second PrimaryOxidesMiddle Agedmedicine.diseaseSecond PrimaryEarly DiagnosisOncologychemistryCancer researchFemalebusinessSettore MED/15 - Malattie del SangueCurrent opinion in oncology
researchProduct

Therapy-Related Myeloid Neoplasms in Patients With Acute Promyelocytic Leukemia Treated With All-Trans-Retinoic Acid and Anthracycline-Based Chemothe…

2010

Purpose We analyzed the incidence, risk factors, and outcome of therapy-related myeloid neoplasms (t-MNs) in patients with acute promyelocytic leukemia (APL) in first complete remission (CR). Patients and Methods From 1996 to 2008, 1,025 patients with APL were enrolled onto three sequential trials (LPA96, LPA99, and LPA2005) of the Programa Español para el Tratamiento de Enfermedades Hematológicas and received induction and consolidation therapy with all-trans-retinoic acid (ATRA) and anthracycline-based chemotherapy. Results Seventeen of 918 patients who achieved CR developed t-MN (10 with < 20% and seven with ≥ 20% of bone marrow blasts) after a median of 43 months from CR. Partial and…

Acute promyelocytic leukemiaAdultMaleCancer Researchmedicine.medical_specialtyMyeloidAnthracyclinemedicine.medical_treatmentTretinoinGastroenterologyLeukemia Promyelocytic AcuteTretinoinRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCumulative incidenceAnthracyclinesProspective StudiesAgedChemotherapybusiness.industryIncidenceNeoplasms Second PrimaryMiddle Agedmedicine.diseasePrognosisSurgeryLeukemiamedicine.anatomical_structureTreatment OutcomeOncologyFemaleBone marrowbusinessBone Marrow Neoplasmsmedicine.drugJournal of Clinical Oncology
researchProduct

Risk of second primary cancers in women diagnosed with endometrial cancer in G erman and S wedish cancer registries

2017

Along with the increasing incidence and favorable prognosis, more women diagnosed with endometrial cancer may develop second primary cancers (SPCs). We aimed at investigating risk of SPCs after endometrial cancer in Germany and Sweden to provide insight into prevention strategies for SPCs. Endometrial cancer patients diagnosed at age ≥15 years in Germany during 1997-2011 and in Sweden nationwide during 1997-2012 were selected. Standardized incidence ratios (SIRs), calculated as the ratio of observed to expected numbers of cases, were used to assess the risk of a specific second cancer after endometrial cancer for both German and Swedish datasets. Among 46,929 endometrial cancer survivors in…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyAdolescentYoung Adult03 medical and health sciences0302 clinical medicineRisk FactorsGermanyInternal medicineEpidemiology of cancermedicineHumansRegistriesYoung adultAgedAged 80 and overSwedenGynecologyCancer preventionbusiness.industryIncidenceEndometrial cancerIncidence (epidemiology)CancerNeoplasms Second PrimaryMiddle Agedmedicine.diseaseEndometrial NeoplasmsCancer registry030104 developmental biologyOncology030220 oncology & carcinogenesisFemalebusinessKidney cancerInternational Journal of Cancer
researchProduct